Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East

Published: 2025-05-27 09:05:44 ET IBRX

Published on 05/27/2025 at 09:05

ImmunityBio, Inc. announced the signing of a strategic Memorandum of Understanding (MOU) with the Ministry of Investment of Saudi Arabia (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC). This multi-party collaboration will introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East, paving the way for a new era of immune-restorative therapies for cancer patients. Together, the partners will assess integration of the BioShield platform across clinical ecosystems and jointly establish a training and research hub to serve as a regional nucleus for immune-restorative therapies.

The BioShield platform, powered by Anktiva®? (nogapendekin alfa inbakicept--rep represents a paradigm shift in cancer care. Unlike conventional treatments including chemotherapy and radiation that suppress immune cells, BioShield preserves and activates the immune system's natural killer cells and T cells to restore immune function and improve outcomes.